I-MAB gets exclusive rights to myeloma candidate from MorphoSys
MorphoSys AG granted I-Mab Biopharma exclusive rights in China, Taiwan, Hong Kong, and Macau to MOR202, a CD38 antagonist in Phase II trials for relapsed/refractory multiple myeloma.
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.